# A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China

Source: https://onco.cc/trials/nct06640049/  
OnCo record `nct06640049` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Dostarlimab in colorectal cancer, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China is a phase 2 interventional study registered as NCT06640049 by GlaxoSmithKline, with 23 participants enrolled, started 2024-10-17 and due to reach its primary completion in 2027-10-24. Interventions recorded: Dostarlimab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06640049
- Phase: 2
- Setting: A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer in China
- Sponsor: GlaxoSmithKline
- Enrolled: 23

## Sources

- ClinicalTrials.gov NCT06640049: https://clinicaltrials.gov/study/NCT06640049

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct06640049.json